Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare Biotechnology

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Recognizing value & Droning synergies will develop

<< Previous

Bullboard Posts

Next >>

Comment by CyKillon Jan 23, 2021 5:45am

120 Views

Post# 32367188

RE:Recognizing value & Droning synergies will develop

GoldenInvestor wrote: Over time. I think we will see significant synergies take hold sooner than later...

I don't think we will have any significant synergies atleast this year. If I remember correctly, some Latam govt issued a decree prohibiting letting go employees in pandemic, so difficult to rightsize the organisation in the current environment. Also, winters will be starting in 3-4 months in LATAM, and we might see another COVID19 wave that would probably hinder any progress on the ground. Just my opnion, without any special insight.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks